CA-GREENPARK-SPORTS
16.12.2020 17:02:35 CET | Business Wire | Press release
GreenPark Sports , the fan-focused publisher and developer of mobile games and social experiences, has announced a global partnership with world-renowned Spanish soccer league LaLiga . GreenPark and LaLiga will work closely together in the multiyear deal to engage next-generation soccer fans in GreenPark’s virtual metaverse for sports and esports fans.
With the commitment to captivate local fan communities and networks, the partnership allows fans to select any of the league’s 20 teams as they flex their team spirit using their in-game avatar. As a GreenPark “superfan,” players will also be able to digitally outfit their avatar with authentic and custom LaLiga team gear, while participating in obstacle course runs, dance battles and various other minigames including some that leverage real-time scoring and statistics. In-game currency can also be exchanged for exclusive rewards and digital fan-gear.
“As one of the leading sports brands in the world, we continuously explore all the unique avenues to connect and engage with our fans globally. This partnership will let us get closer to the gaming community worldwide and offer them the possibility to follow the best soccer in the world, LaLiga” said Oscar Mayo, Head of Marketing and International Development at LaLiga. “We are confident that our partnership with GreenPark Sports will help us reach the next generation of fans by offering an exciting virtual arena for them to be a part of.”
Launching in early 2021, GreenPark Sports creates immersive social platforms for the new generation of sports and esports fans. The free-to-play mobile app will offer in-game experiences, allowing fans to battle it out through a variety of challenges and become the undisputed “Best Fans” of their league. Players can earn rewards virtually as well as exclusive tangible rewards.
“LaLiga represents some of the largest brands in all of sport, and the fueling passion from their fans is unparalleled,” said Tony Grillo, Vice President of Business Operations at GreenPark. “We look forward to co-creating special experiences for their fans and seeing them bring their energy into GreenPark!”
The new partnership follows GreenPark’s announcements with the National Basketball Association (NBA) earlier this month and the League of Legends Championship Series (LCS) in January.
To stay updated with the latest news on GreenPark Sports, follow the organization via its official website here , and on Twitter and Facebook .
Assets: GreenPark x LaLiga Partnership
ABOUT GREENPARK
Founded in 2018, GreenPark Sports is a publisher and developer of fan-forward, digital experiences and mobile games for the new generation of sports and esports fans. Co-founded by Chad Hurley (YouTube Co-founder / former CEO), Nick Swinmurn (Zappos founder / former CEO) and Ken Martin (BLITZ Co-founder / former CCO), GreenPark Sports was created to reimagine the role of today’s digitally-native fan as an active participant in the live sports/esports they love.
ABOUT LALIGA
LaLiga is a global, innovative and socially responsible organisation which is a leader in the leisure and entertainment sector. It is a private sports association composed of the 20 public limited sports companies (SADs) and clubs of LaLiga Santander and the 22 of LaLiga SmartBank, and is responsible for organising professional football competitions in Spain. In the 2019/20 season, LaLiga reached 2.8 billion people globally. With its headquarters in Madrid (Spain), it is present in 55 countries through eleven offices and 46 delegates. The organisation carries out its social work through its foundation and was the world's first professional football league to establish a league for intellectually challenged footballers: LaLiga Genuine Santander.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005356/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom